- Clinical-stage biopharma Corvus Pharmaceuticals ( NASDAQ: CRVS ) on Monday said an investigational new drug application to start a phase 1/1b trial of monoclonal antibody mupadolimab had been approved by China's drug regulator.
- The study was approved by the Center for Drug Evaluation of the China National Medical Products Administration, and will be conducted by Angel Pharmaceuticals, CRVS' partner in the Asian country.
- Mupadolimab is being evaluated for the treatment of patients with relapsed refractory non-small cell lung cancer and head and neck squamous cell cancers.
- Angel Pharma, a privately-held biopharma, was co-founded by CRVS to develop its pipeline in greater China.
- Angel Pharma licensed the rights from CRVS to develop, make and commercialize mupadolimab in greater China, Corvus ( CRVS ) said in a statement .
- CRVS stock +5% to $0.76 after hours.
For further details see:
Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China